Meeting
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS.
Authors
Karim Fizazi
Gustave Roussy and University of Paris-Saclay, Villejuif, France
Karim Fizazi , Neal D. Shore , Matthew Raymond Smith , Rodrigo Ramos , Robert J. Jones , Guenter Niegisch , Egils Vjaters , Jorge A. Ortiz , Steve Liang , Yuan Wang , Shankar Srinivasan , Toni Sarapohja , Frank Verholen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02200614
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 256)
DOI
10.1200/JCO.2022.40.6_suppl.256
Abstract #
256
Poster Bd #
L7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Physician preferences for nonmetastatic castration-resistant prostate cancer treatments: A discrete choice experiment among men in mainland China.
First Author: Yu Fan
Poster
2021 Genitourinary Cancers Symposium
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
First Author: Tomasz M. Beer
Poster
2020 ASCO Virtual Scientific Program
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
First Author: Karim Fizazi
Poster
2020 ASCO Virtual Scientific Program
DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.
First Author: Evan Y. Yu